Journal: Oncology Letters

Article Title: Systemic transduction of p16 INK4a antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice

doi: 10.3892/ol.2018.9655

Figure Lengend Snippet: Histological results of the lungs of mice in (A) control group with no p16 MIS peptide treatment (B) single p16 MIS peptide treatment group (p16×1) and (C) triple p16 MIS peptide treatment group (p16×3). Histological data of the lung at the 14th experimental day after MBT-2 administration via the mouse tail vein demonstrates that lung metastases are inhibited in number and size in the groups administered with the p16MIS peptide (B and C), compared with the control group (A). In the group with triple p16MIS peptide injection (C), metastases was rarely observed in the lung (magnification, ×40). Note that the arrows indicate metastatic nodules.

Article Snippet: Mouse model for lung metastases Six-week-old female C3H/He mice were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan).

Techniques: Control, Injection

Journal: Oncology Letters

Article Title: Systemic transduction of p16 INK4a antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice

doi: 10.3892/ol.2018.9655

Figure Lengend Snippet: Number and size of lung metastases of MBT-2 cells control group and groups following p16 MIS peptide treatment. (A) Number of lung metastases in control group and groups with single and triple p16 MIS peptide treatment. For the number of lung metastases, the significance for control vs. p16×1 or p16×3 was P=0.0087 and P=0.0029, respectively (B) Size of lung metastases in control group and groups with single and triple p16 MIS peptide treatment. The significance for the area of metastases was P=0.0183 and P=0.0296 for control vs. p16×1 or p16×3, respectively. Quantitative evaluation demonstrated that the number (A) and size (B) of metastases in histological sections were statistically different between the p16 MIS peptide transduction and control groups. p16×1, single treatment of p16 MIS peptide; p16×3, triple treatments of p16 MIS peptide.

Article Snippet: Mouse model for lung metastases Six-week-old female C3H/He mice were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan).

Techniques: Control, Transduction

Journal: Oncology Letters

Article Title: Systemic transduction of p16 INK4a antitumor peptide inhibits lung metastasis of the MBT-2 bladder tumor cell line in mice

doi: 10.3892/ol.2018.9655

Figure Lengend Snippet: Histological findings of H&E staining, phosphorylated Rb immunohistochemistry and TUNEL staining in lung metastasis of control and p16 MIS peptide treatment group. (A) H&E staining of control group. (B) Phosphorylated Rb immunostaining of control group. (C) TUNEL staining of control group. (D) H&E staining of p16 MIS peptide treatment group. (E) Phosphorylated Rb immunostaining of p16 MIS peptide treatment group. (F) TUNEL staining of p16 MIS peptide treatment group. Rb phosphorylation decreased in p16 MIS peptide treatment group (E) compared with control group (B). In TUNEL staining, apoptosis was detected in p16 MIS peptide treatment group (F) compared with control group (C). Magnification, ×400. H&E, hematoxylin and eosin.

Article Snippet: Mouse model for lung metastases Six-week-old female C3H/He mice were obtained from Charles River Laboratories Japan, Inc. (Yokohama, Japan).

Techniques: Staining, Immunohistochemistry, TUNEL Assay, Control, Immunostaining, Phospho-proteomics

Journal: Cancers

Article Title: Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy

doi: 10.3390/cancers13205202

Figure Lengend Snippet: Selected prospective studies evaluating thermal ablation for oligometastatic NSCLC patients.

Article Snippet: Although randomized controlled trials are needed to delineate the role of each therapy in the management of oligometastatic NSCLC patients, a growing body of evidence suggests that TA is not inferior to lung resection or SBRT in carefully selected patients, as shown by Hasegawa et al. for oligometastatic colorectal lung metastases ≤3 cm [ ], or by a large series on lung metastases [ ] that yielded similar local control rates and similar OS.

Techniques:

Journal: Cancers

Article Title: Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy

doi: 10.3390/cancers13205202

Figure Lengend Snippet: Selected retrospective studies evaluating thermal ablation for oligometastatic NSCLC patients.

Article Snippet: Although randomized controlled trials are needed to delineate the role of each therapy in the management of oligometastatic NSCLC patients, a growing body of evidence suggests that TA is not inferior to lung resection or SBRT in carefully selected patients, as shown by Hasegawa et al. for oligometastatic colorectal lung metastases ≤3 cm [ ], or by a large series on lung metastases [ ] that yielded similar local control rates and similar OS.

Techniques:

Journal: Cancers

Article Title: Current Management of Oligometastatic Lung Cancer and Future Perspectives: Results of Thermal Ablation as a Local Ablative Therapy

doi: 10.3390/cancers13205202

Figure Lengend Snippet: Proposed decision algorithm for local ablation therapy of oligometastatic non-small cell lung carcinoma.

Article Snippet: Although randomized controlled trials are needed to delineate the role of each therapy in the management of oligometastatic NSCLC patients, a growing body of evidence suggests that TA is not inferior to lung resection or SBRT in carefully selected patients, as shown by Hasegawa et al. for oligometastatic colorectal lung metastases ≤3 cm [ ], or by a large series on lung metastases [ ] that yielded similar local control rates and similar OS.

Techniques: